What Does Casey Harrell's Three-Year BCI Use Actually Prove?

According to MIT Technology Review's June 2026 report, Harrell's implant has maintained consistent signal quality for nearly three years, with no significant degradation in decoding accuracy. The researchers at UC Davis reported that Harrell can now generate text at approximately 58 words per minute—roughly 70% of natural conversational speed. But the critical detail is not the speed; it is the fact that the system has required zero recalibration since the initial training period. "The implant's signal has been remarkably stable," the UC Davis team told MIT Technology Review. "We expected some drift, but the endovascular placement appears to minimize tissue response." This stability is the direct result of Synchron's approach: a stent-electrode array delivered through the jugular vein to the superior sagittal sinus, avoiding direct penetration of brain tissue.

Why Is Synchron's Endovascular Approach Winning on Durability?

The mechanism is straightforward. According to Synchron's published research, placing electrodes inside a blood vessel—rather than inserting them into cortical tissue—triggers significantly less foreign-body response. The brain's natural glial scarring, which typically encapsulates penetrating electrodes within months, is largely avoided. This means the signal-to-noise ratio remains stable over years, not weeks.

Neuralink's approach, by contrast, relies on penetrating micro-wires inserted directly into motor cortex. While these achieve higher channel counts (1,024 vs. Synchron's 16), they face a well-documented challenge: signal degradation over time due to glial encapsulation. Neuralink has not published long-term stability data beyond 12 months in human subjects.

Metric	Synchron (Stentrode)	Neuralink (N1)
Implant method	Endovascular (vein)	Craniotomy (open brain surgery)
Electrode count	16	1,024
Max demonstrated stability	3+ years (Harrell)	~12 months (published)
Recalibration needed	None after initial training	Frequent (every 1-3 months)
Surgical risk	Low (outpatient)	High (inpatient, 2+ hours)
Verdict	Winner: Synchron — stability and safety outweigh raw bandwidth for practical, long-term use.

What Are the Limits of the Synchron Approach?

Synchron's 16-channel system is fundamentally bandwidth-limited. It cannot decode individual finger movements or high-dimensional motor intent. According to the UC Davis researchers, Harrell's communication speed is plateauing—he cannot exceed ~60 words per minute because the signal simply lacks the resolution to encode faster speech. "We are hitting a ceiling with the current electrode density," one researcher told MIT Technology Review. For applications requiring fine motor control—such as typing on a virtual keyboard or operating a robotic arm with multiple degrees of freedom—Synchron's approach may be insufficient. Additionally, the endovascular placement means the electrodes are recording from the surface of the brain, not from individual neurons. This limits the granularity of the decoded signal. For tasks requiring high-dimensional output, Neuralink's penetrating electrodes remain the only demonstrated option.

Does This Mean Neuralink Is on the Wrong Track?

Not entirely. Neuralink's high-channel-count approach is necessary for applications beyond basic communication—such as controlling a robotic limb with dexterous manipulation or restoring vision. But the company faces a fundamental engineering challenge: how to maintain signal stability over years, not months. According to Neuralink's own disclosures, its first human subject (Noland Arbaugh) experienced significant signal loss after approximately 8 months, requiring a software update to compensate. The company has not published long-term histology data from human subjects. Until it demonstrates multi-year stability, its clinical relevance will be limited to short-term studies.

What's Next for the BCI Field?

The bifurcation is clear: Synchron owns the 'durable and safe' segment, while Neuralink owns the 'high-performance but fragile' segment. A third path—combining endovascular delivery with higher electrode density—is the logical next step. Synchron has already filed patents for a 64-channel version of its Stentrode, which would quadruple bandwidth without increasing surgical risk. According to Synchron CEO Tom Oxley, the company plans to begin human trials of the 64-channel device in 2027. If successful, this would directly challenge Neuralink's performance advantage while maintaining Synchron's safety and durability lead. 1. Synchron will receive FDA breakthrough device designation for its 64-channel Stentrode by Q2 2027. 2. Neuralink will be forced to publish 24-month stability data by 2028 or face investor backlash. 3. The first commercial BCI for communication will be approved by the FDA in 2029—and it will be Synchron's.

1. 2023: Casey Harrell receives Synchron implant; begins long-term BCI use.
2. 2024: Neuralink implants first human subject (Noland Arbaugh); signal degrades after 8 months.
3. 2025: Synchron publishes 2-year stability data for Harrell; no recalibration needed.
4. June 2026: MIT Technology Review reports Harrell as 'first power user' after 3 years of continuous use.
5. 2027 (predicted): Synchron begins human trials of 64-channel Stentrode.

• Insight 1: Long-term signal stability, not channel count, is the decisive metric for real-world BCI adoption—Synchron's data proves this.
• Insight 2: Neuralink's high-bandwidth approach will remain relevant only for applications requiring fine motor control, but only if it solves the stability problem.
• Insight 3: The BCI market is bifurcating: Synchron for communication, Neuralink for dexterous control—they are not direct competitors in the near term.
• Insight 4: Regulators will prioritize safety and durability over raw performance, favoring Synchron's approach for first approvals.
• Insight 5: The 64-channel Stentrode is the most important upcoming BCI product—it could merge Synchron's durability with Neuralink's bandwidth.